Minirin (Desmopressin Acetate)

Desmopressin is a synthetic vasopressin analogue that selectively activates V2 receptors in the kidney’s collecting ducts. This triggers a cascade that increases cyclic AMP, promoting insertion of aquaporin‑2 water channels into the tubular membrane, which enhances water reabsorption and concentrates urine. In endothelial cells, V2 activation releases von Willebrand factor and factor VIII, aiding haemostasis.

The dose of Minirin is individualized and set by a qualified prescriber based on the specific indication, patient age, weight, renal function, and response to therapy. Clinicians adjust the regimen according to clinical monitoring, such as urine output for diabetes insipidus or bleeding parameters for haemostatic use.

Safety data for desmopressin in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by the treating physician in consultation with the patient.

To order Minirin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and any necessary import documentation.

Compared with natural vasopressin, desmopressin has a longer half‑life, greater selectivity for V2 receptors, and minimal vasoconstrictive (V1) activity, reducing cardiovascular side effects. It is also more potent than some oral antidiuretic agents, allowing lower dosing frequencies, but requires careful monitoring for water‑balance disturbances.

Minirin should be stored at room temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and avoid freezing. Follow any additional handling instructions provided on the label.

Minirin is supplied as an injectable solution and may be given intramuscularly, intravenously, or subcutaneously according to the prescriber’s instructions. The route, injection site, and volume are determined by the indication and patient‑specific factors.

The most serious risks include severe hyponatremia, which can lead to seizures, coma, or cerebral edema, and water intoxication. Patients should be monitored for rapid weight gain, low serum sodium, and neurological symptoms, especially when fluid intake is not restricted.

Minirin is contraindicated in patients with known hypersensitivity to desmopressin or any excipients, in those with uncontrolled hypertension, and in individuals with conditions predisposing them to fluid overload or severe hyponatremia, such as certain renal or cardiac diseases, unless closely supervised.